Skip to content

Study · Non-randomized trial · 2004

2 results

Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy.

Sverrisdóttir A, Fornander T, Jacobsson H, von Schoultz E, Rutqvist LE

Journal of clinical oncology : official journal of the American Society of Clinical Oncology1 Sept 2004Cited by 104 (Europe PMC)

PMID15365065 (opens in a new tab)DOI10.1200/jco.2004.08.148 (opens in a new tab)PepBankPUB-15365065
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialSafety outcome

    In premenopausal women with breast cancer, goserelin alone reduced bone mineral density by 5% after 2 years (P <.001).

    In plain wordsIn premenopausal women with breast cancer, bone density fell by 5% after 2 years of goserelin alone.

    Peptide
    Goserelin
    Outcome
    DecreaseTotal-body bone mineral density
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 2 yearsAs given in this study (human).

    Measurements

    Mean bone mineral density change
    −5%
    goserelin alone at 2 years

    Source sentences

    Summary
    After 2 years of treatment, there was a significant loss of bone mineral density (mean change, -5%; P <.001) in the women receiving goserelin alone.
    2 context sentences
    Summary · context
    We recruited 89 women from two centers in Stockholm participating in a randomized multicenter trial of three different endocrine approaches in the adjuvant setting (Zoladex in Premenopausal Patients Trial).
    Summary · context
    The women were assigned to receive the LHRH agonist goserelin with or without tamoxifen, tamoxifen alone, or no endocrine therapy.
  2. 02HumanNon-randomized trialSafety outcome

    In women previously treated with goserelin alone, bone mineral density partially recovered by 1.5% one year after treatment cessation (P =.02).

    In plain wordsIn women previously given goserelin alone, bone density partially recovered one year after treatment stopped.

    Peptide
    Goserelin
    Outcome
    IncreaseBone mineral density recovery
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Mean bone mineral density change
    1.5%
    one year after cessation

    Source sentences

    Summary
    One year after cessation of treatment, the goserelin group alone showed a partial recovery from bone loss (mean change, 1.5%; P =.02).
    2 context sentences
    Summary · context
    We recruited 89 women from two centers in Stockholm participating in a randomized multicenter trial of three different endocrine approaches in the adjuvant setting (Zoladex in Premenopausal Patients Trial).
    Summary · context
    The women were assigned to receive the LHRH agonist goserelin with or without tamoxifen, tamoxifen alone, or no endocrine therapy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.